Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Rinvoq TM

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.

Active ingredients: upadacitinib

Brand name

(ARTG)

: RINVOQ upadacitinib 15 mg modified release tablet blister pack

Download the Consumer Medicine Information Leaflet

Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website

What this medicine is used for

(ARTG)

Rheumatoid Arthritis,RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).,RINVOQ may be used as monotherapy or in combination with methotrexate or other conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).,Psoriatic Arthritis,RINVOQ is indicated for the treatment of moderate to severe active psoriatic arthritis in adult patients who have responded inadequately to, or are intolerant to one or more DMARDs.,RINVOQ may be used as monotherapy or in combination with a non-biological DMARD.,Non-radiographic Axial Spondyloarthritis,RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) change, who have responded inadequately to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).,Ankylosing Spondylitis,RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis.,Atopic Dermatitis,RINVOQ is indicated for use in adults and adolescents aged 12 years and above who weigh at least 40 kg, for the treatment of moderate to severe atopic dermatitis which is inadequately controlled with active topical pharmacotherapies and for whom systemic therapy is indicated.,Ulcerative Colitis,RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis, who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biological medicine.Crohns Disease,RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohns disease, who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biological medicine.

How to use this medicine

(ARTG)

This medicine contains one component only.

Component :

  • Tablet, modified release
  • Oral
  • RINVOQ 15 mg tablets are purple, biconvex oblong in shape with dimensions of 14 x 8 mm and debossed with 'a15' on one side.

Storage conditions

(ARTG)

  • Store below 30 degrees Celsius
  • Protect from Moisture
  • Shelf lifetime is 24 Months.

Do I need a prescription ?

(ARTG)

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.

  • 28 tablets pack
  • 7 tablets (starter pack) pack

Is this medicine subsidised ?

(PBS)

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.

Pregnant or planning a pregnancy ?

(AHT)

For the active ingredient upadacitinib

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Reporting side effects

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.

Back to top back to top

Need more information?

These trusted information partners have more on this topic.

Top results

New safety warning for medicines used in arthritis and other inflammatory conditions | Therapeutic Goods Administration (TGA)

A safety warning has been added to a class of medicines called Janus Kinase inhibitors used for chronic inflammatory conditions.

Read more on TGA – Therapeutic Goods Administration website

Medication for IBD – Crohn’s & Colitis Australia (CCA)

For more than 30 years, Crohn’s & Colitis Australia has been empowering the more than 100,000 Australian's living with Crohn’s disease or IBD.

Read more on Crohn's & Colitis Australia website

Healthdirect 24hr 7 days a week hotline

24 hour health advice you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information and advice

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Queensland Government logo Government of South Australia, health department logo Tasmanian government logo Victorian government logo Government of Western Australia, health department logo

Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and present.